Replies to post #17869 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Any opinion on the long range monoclonal antibody side of this story? Looks like a great long term story for bringing down the cost of some expensive therapies.

It sounds promising, but where’s the beef? If GTC’s platform is capable of developing superior mAbs, e.g. by enhancing ADCC to improve efficacy against cancer, then GTC needs to start monetizing this technology. Mere talk is not going to cut it.